Citius Pharmaceuticals Inc Financials
This page shows Citius Pharmaceuticals Inc (CTXR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn is being funded externally as liquidity tightens, making the balance sheet carry more of the business than sales do.
From FY2023 to FY2025, total liabilities rose from$12.2M to$53.4M , showing the balance sheet, rather than operations, took on a much larger funding role. In FY2025, financing inflows of$33.3M exceeded the operating cash outflow of$26.6M , which is why liquidity was preserved at all.
The spending mix has shifted away from R&D: research spending fell from
A larger share of assets is now tied up in inventory, which increased from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Citius Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Citius Pharmaceuticals Inc carries a low D/E ratio of 0.79, meaning only $0.79 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Citius Pharmaceuticals Inc's current ratio of 0.62 is below the typical benchmark, resulting in a score of 7/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Citius Pharmaceuticals Inc generates a -58.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -56.3% the prior year.
Citius Pharmaceuticals Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Citius Pharmaceuticals Inc generates $0.67 in operating cash flow (-$26.6M OCF vs -$39.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Citius Pharmaceuticals Inc earns $-774.4 in operating income for every $1 of interest expense (-$38.5M vs $50K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Citius Pharmaceuticals Inc reported -$39.7M in net income in fiscal year 2025. This represents a decrease of 0.8% from the prior year.
Citius Pharmaceuticals Inc earned $-3.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 43.4% from the prior year.
Cash & Balance Sheet
Citius Pharmaceuticals Inc held $4.3M in cash against $0 in long-term debt as of fiscal year 2025.
Citius Pharmaceuticals Inc had 18M shares outstanding in fiscal year 2025. This represents an increase of 149.3% from the prior year.
Margins & Returns
Citius Pharmaceuticals Inc's ROE was -58.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the prior year.
Capital Allocation
Citius Pharmaceuticals Inc invested $9.2M in research and development in fiscal year 2025. This represents a decrease of 23.1% from the prior year.
CTXR Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M-57.7% | $3.9M | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $329K-58.3% | $789K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $1.3M-57.6% | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.6M+2.1% | $1.6M | N/A | $1.6M-57.0% | $3.8M+77.1% | $2.1M | N/A | $2.8M |
| SG&A Expenses | $26.4M+361.3% | $5.7M | N/A | $4.4M-7.2% | $4.8M-11.1% | $5.4M | N/A | $4.8M |
| Operating Income | -$32.2M-257.0% | -$9.0M | N/A | -$8.8M+22.0% | -$11.3M-12.2% | -$10.0M | N/A | -$10.6M |
| Interest Expense | $33K-78.8% | $156K | N/A | $12K | N/A | N/A | N/A | N/A |
| Income Tax | -$231K-187.5% | $264K | N/A | $264K0.0% | $264K0.0% | $264K | N/A | $144K |
| Net Income | -$28.1M-199.2% | -$9.4M | N/A | -$9.2M+20.0% | -$11.5M-12.0% | -$10.3M | N/A | -$10.6M |
| EPS (Diluted) | $-0.95-150.0% | $-0.38 | N/A | $-0.80+37.0% | $-1.27+2.3% | $-1.30 | N/A | $-1.57 |
CTXR Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $132.5M-5.6% | $140.4M+7.2% | $130.9M+2.6% | $127.7M+5.1% | $121.5M+0.6% | $120.7M+3.5% | $116.7M+20.1% | $97.1M |
| Current Assets | $31.7M-16.5% | $37.9M+35.8% | $27.9M+13.5% | $24.6M+33.9% | $18.4M+0.3% | $18.3M+28.9% | $14.2M-49.2% | $28.0M |
| Cash & Equivalents | $4.6M-40.6% | $7.7M+81.6% | $4.3M-30.2% | $6.1M+22956.1% | $26K-97.6% | $1.1M-66.2% | $3.3M-81.8% | $17.9M |
| Inventory | $22.7M+0.1% | $22.6M+1.6% | $22.3M+29.5% | $17.2M+12.2% | $15.3M+6.7% | $14.4M+73.9% | $8.3M | N/A |
| Accounts Receivable | $1.1M-73.4% | $4.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M |
| Total Liabilities | $63.5M+35.2% | $46.9M-12.1% | $53.4M-11.2% | $60.1M+3.8% | $57.9M+11.8% | $51.8M+21.7% | $42.5M+293.8% | $10.8M |
| Current Liabilities | $55.0M+44.0% | $38.2M-14.9% | $44.9M-13.4% | $51.8M+3.9% | $49.9M+11.3% | $44.8M+25.1% | $35.8M+762.6% | $4.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $61.5M-23.0% | $80.0M+18.4% | $67.6M+3.8% | $65.1M+7.3% | $60.7M-7.3% | $65.4M-6.7% | $70.1M-18.2% | $85.7M |
| Retained Earnings | -$268.3M-8.6% | -$247.0M-3.4% | -$238.8M-3.4% | -$230.8M-4.0% | -$222.1M-5.2% | -$211.1M-4.9% | -$201.4M-5.7% | -$190.6M |
CTXR Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M+90.0% | -$13.0M-9.5% | -$11.9M-119.7% | -$5.4M-19.1% | -$4.5M+3.9% | -$4.7M+20.1% | -$5.9M+29.3% | -$8.4M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$600K+86.4% | -$4.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$1.2M-105.9% | $20.9M+32.2% | $15.8M+37.7% | $11.5M+230.9% | $3.5M+34.6% | $2.6M+168.7% | -$3.7M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CTXR Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.3%+0.3pp | 80.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1931.0%-1702.3pp | -228.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -1686.0%-1447.8pp | -238.2% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -45.7%-33.9pp | -11.8% | N/A | -14.1%+4.8pp | -19.0%-3.3pp | -15.7% | N/A | -12.3% |
| Return on Assets | -21.2%-14.5pp | -6.7% | N/A | -7.2%+2.3pp | -9.5%-1.0pp | -8.5% | N/A | -10.9% |
| Current Ratio | 0.58-0.4 | 0.99+0.4 | 0.62+0.1 | 0.47+0.1 | 0.37-0.0 | 0.41+0.0 | 0.40-6.3 | 6.75 |
| Debt-to-Equity | 1.03+0.4 | 0.59-0.2 | 0.79-0.1 | 0.92-0.0 | 0.95+0.2 | 0.79+0.2 | 0.61+0.5 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.62), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Citius Pharmaceuticals Inc profitable?
No, Citius Pharmaceuticals Inc (CTXR) reported a net income of -$39.7M in fiscal year 2025.
What is Citius Pharmaceuticals Inc's return on equity (ROE)?
Citius Pharmaceuticals Inc (CTXR) has a return on equity of -58.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Citius Pharmaceuticals Inc's operating cash flow?
Citius Pharmaceuticals Inc (CTXR) generated -$26.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Citius Pharmaceuticals Inc's total assets?
Citius Pharmaceuticals Inc (CTXR) had $130.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Citius Pharmaceuticals Inc spend on research and development?
Citius Pharmaceuticals Inc (CTXR) invested $9.2M in research and development during fiscal year 2025.
What is Citius Pharmaceuticals Inc's current ratio?
Citius Pharmaceuticals Inc (CTXR) had a current ratio of 0.62 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Citius Pharmaceuticals Inc's debt-to-equity ratio?
Citius Pharmaceuticals Inc (CTXR) had a debt-to-equity ratio of 0.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Citius Pharmaceuticals Inc's return on assets (ROA)?
Citius Pharmaceuticals Inc (CTXR) had a return on assets of -30.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Citius Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Citius Pharmaceuticals Inc (CTXR) had $4.3M in cash against an annual operating cash burn of $26.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Citius Pharmaceuticals Inc's Piotroski F-Score?
Citius Pharmaceuticals Inc (CTXR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Citius Pharmaceuticals Inc's earnings high quality?
Citius Pharmaceuticals Inc (CTXR) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Citius Pharmaceuticals Inc cover its interest payments?
Citius Pharmaceuticals Inc (CTXR) has an interest coverage ratio of -774.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Citius Pharmaceuticals Inc?
Citius Pharmaceuticals Inc (CTXR) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.